Sources — every claim, traceable to a primary source

A note on sources

Every numeric and propositional claim on the addictions microsite is sourced from this page. The hierarchy of evidence used: Cochrane reviews and large RCTs first; multi-cohort meta-analyses next; named-author primary papers in major journals (NEJM, BMJ, Lancet, JAMA, Nature, PLoS, Annual Review); official agency reports (WHO, NIAAA, NIDA, EMCDDA, NICE, OHID, IAS, ASH, IFS); think-tank and advocacy papers (IEA, Frontier Economics, TBI, McKinsey, Resolution Foundation) cited with funding source disclosed; and books by named authorities with publication date. Newspaper and magazine pieces appear only where they aggregate primary work or where they are themselves the editorial position being characterised (Spiked).

Pathway sources

The shared circuit and the dopamine system

• Volkow ND, Wang G-J, Tomasi D, Baler RD. Unbalanced neuronal circuits in addiction. Journal of Neuroscience, 2013.

Wanting vs liking — Berridge incentive-sensitization

• Robinson TE & Berridge KC. The incentive-sensitization theory of addiction 30 years on. Annual Review of Psychology, 2025.
• Berridge KC & Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. American Psychologist, 2016.

Allostasis — Koob's opponent-process

• Koob GF & Le Moal M. Drug Addiction, Dysregulation of Reward, and Allostasis. Neuropsychopharmacology, 2001.
• Koob GF & Le Moal M. Neurobiological mechanisms for opponent motivational processes in addiction. Philosophical Transactions of the Royal Society B, 2008.

D2 downregulation — Volkow imaging

• Volkow ND et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. 1993.
• Volkow ND et al. Low level of brain dopamine D2 receptors in methamphetamine abusers. 2001.
• Goldstein RZ & Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nature Reviews Neuroscience, 2011.

Set-point physiology — Leibel / Rosenbaum / Hirsch

• Leibel RL, Rosenbaum M, Hirsch J. Changes in Energy Expenditure Resulting from Altered Body Weight. NEJM, 1995.
• Rosenbaum M & Leibel RL. Adaptive thermogenesis in humans. Obesity, 2016 update.
• Rockefeller summary of the set-point research programme.

Alcohol

• Grant BF et al. Epidemiology of DSM-5 Alcohol Use Disorder: NESARC-III. JAMA Psychiatry, 2015.

Opioids

• StatPearls — Mu Opioid Receptors review.
• Mechanism review, Frontiers in Neuroscience, 2025.
• Purdue Pharma / OxyContin history, NCBI overview.

Food — Yale Food Addiction Scale and UPFA

• Gearhardt AN, FAST Lab — Yale Food Addiction Scale.
• Gearhardt AN et al. Social, clinical, and policy implications of ultra-processed food addiction. BMJ, 2023.
• Moss M. Salt Sugar Fat. Random House, 2013.
• Kessler DA. The End of Overeating. Rodale, 2009.

Pornography — DSM/ICD position

• Reid RC & Kafka MP. Controversies about hypersexual disorder and the DSM-5. Current Sexual Health Reports, 2014.
• Kraus SW et al. Compulsive sexual behaviour disorder in the ICD-11. World Psychiatry, 2018.
• Voon V et al. PLoS One 2014, Cambridge press summary.

Mental toll

• Luoma JB et al. The shame spiral of addiction. Psychology of Addictive Behaviors, 2022.

Costs sources

UK / NHS — alcohol

• Institute of Alcohol Studies. £27.4 billion cost of alcohol harm in England every year. 2024.
• British Liver Trust summary of IAS 2024.
• Drinks Business critique of IAS methodology, 2024.

UK / NHS — obesity

• LGA briefing on Foresight 2007 and obesity cost-of-illness lineage, 2025.
• OHID / DHSC, ~£6.5bn NHS obesity spend per year.
• Frontier Economics. The full cost of obesity in the UK. Commissioned by Novo Nordisk, 2022.
• Tony Blair Institute. Unhealthy Numbers. 2024.
• IFS Report R266. The costs of obesity. 2023.

Tobacco

• ASH 2024 — cost of smoking £21.8bn.
• ASH — Economic Impact of Smoking.

Opioids — US cost-of-illness

• Florence C et al. Economic burden of opioid use disorder and fatal opioid overdose in the US, 2017. Drug & Alcohol Dependence, 2021.
• Joint Economic Committee. Cost of opioid epidemic, 2020 update. 2022.

Snowdon / IEA

• Snowdon C. Killjoys: A Critique of Paternalism. IEA, 2017.
• Snowdon C. Alcohol and the Public Purse. IEA Discussion Paper 63, 2015.
• Snowdon C & Tovey M. Smoking and the Public Purse. IEA Discussion Paper 84, 2017.
• Snowdon C. Defanging the Nanny State. IEA Discussion Paper 131, 2024.
• IEA press release. Drinkers subsidise non-drinkers by £6.5bn each year.
• Public Finance summary of Snowdon & Tovey 2017.
• IEA — What is the net fiscal cost of unhealthy lifestyles?

van Baal — the lifetime-cost finding

• van Baal PHM, Polder JJ, de Wit GA, Hoogenveen RT, Feenstra TL et al. Lifetime medical costs of obesity: Prevention no cure for increasing health expenditure. PLoS Medicine 5(2): e29, 2008.
• PLoS Medicine perspective. Does Preventing Obesity Lead to Reduced Health-Care Costs? 2008.

Opposing case — Sheron, Gilmore, Lancet Commission, ASH, BMA, RCP

• Williams R, Sheron N, Gilmore I et al. Lancet Standing Commission on Liver Disease in the UK — final report. 2019.
• Lancet Commission fourth report, 2017.

Global cost-per-class

• WHO 2021 — $1.4tn tobacco global cost.
• WHO Global Status Report on Alcohol and Health, 2018.
• GBD Alcohol Collaborators. Lancet 2018.
• JEC 2022 — US opioid cost.
• UNODC World Drug Report 2025.
• McKinsey Global Institute. Overcoming obesity: an initial economic analysis. 2014.

Tirzepatide — efficacy, mortality, side-effect data

• Jastreboff AM et al. SURMOUNT-1. NEJM, 2022.
• Garvey WT et al. SURMOUNT-2. Lancet, 2023.
• Aronne LJ et al. SURMOUNT-4. JAMA, 2024.
• Aronne LJ et al. SURMOUNT-5 head-to-head. NEJM, 2025.
• Wilding JPH et al. STEP-1 (semaglutide). NEJM, 2021.
• Lincoff AM et al. SELECT. NEJM, 2023.
• SURPASS-CVOT — tctmd summary, NEJM Dec 2025.
• SURMOUNT-MMO trial design.
• GLP-1 / gallbladder meta-analysis.
• NICE TA1026 — tirzepatide.

Actuarial — life-years lost to obesity / hypertension

• Prospective Studies Collaboration. Lancet, 2009.
• Global BMI Mortality Collaboration. Lancet, 2016.
• Peeters A et al. Framingham life-table. Annals of Internal Medicine, 2003.

Weight stigma — Tomiyama, Puhl

• Major B, Tomiyama AJ & Hunger JM. The negative and bidirectional effects of weight stigma on health. Oxford Handbook of Stigma, 2018.
• Puhl RM. Weight stigma and obesity. Gastroenterology Clinics of North America, 2023.

Treatments sources

Managed Alcohol Programs

• CMAPS — Canadian Managed Alcohol Program Study, UVic.
• Stockwell T et al. Multi-site MAP outcome study. Drug & Alcohol Review, 2018.
• Erickson RA et al. MAPs and alcohol affordability. Drug & Alcohol Review, 2018.
• Pauly B et al. There is a Place — qualitative MAP study. Harm Reduction Journal, 2019.
• Scoping review, Harm Reduction Journal, 2022.
• Seaton House Annex — CMAPS webinar, 2015.
• BCCSU. Operational Guidance for MAPs. 2020.

Portugal — decriminalisation arc

• Hughes CE & Stevens A. What can we learn from the Portuguese decriminalization of illicit drugs? British Journal of Criminology, 2010.
• Hughes & Stevens 2012 re-examination.
• Portugal 20-year retrospective. Substance Abuse Treatment, Prevention, and Policy, 2021.
• Open Society Foundations — Portugal austerity threat.
• TalkingDrugs — Portugal model status.
• Transform Drug Policy Foundation, 2024.
• UNSW DPMP review of Portuguese decriminalisation, 2024.
• Portugal Resident — 2021 overdose data.
• NPR — Lisbon overdose surge, 2024.

RCT and meta-evidence base

• Project MATCH. NIAAA, 1997.
• Project MATCH posttreatment paper.
• Maisel NC et al. Naltrexone & acamprosate meta-analysis. Addiction, 2013.
• Kelly JF et al. Alcoholics Anonymous and Twelve-Step Facilitation. Cochrane Review, 2020.
• Sordo L et al. Mortality risk during and after opioid substitution treatment. BMJ, 2017.
• Lee JD et al. Extended-release naltrexone for criminal-justice-involved adults with opioid use disorder. NEJM, 2016.
• EMCDDA. Heroin-assisted treatment — insights monograph.
• Contingency management — AJP "Call to Action" 2024.
• O'Brien PE et al. Long-term bariatric surgery outcomes. 2018.
• CBT for obesity meta-analysis. Behaviour Research & Therapy, 2020.
• Briken P et al. CSBD treatment systematic review. Journal of Behavioral Addictions, 2022.
• Recovery Research Institute — residential treatment review.

Policy sources

• US Surgeon General. Youth Violence: A Report of the Surgeon General. 2001 — DARE listed as "Does Not Work".
• US General Accounting Office. Youth Illicit Drug Use Prevention: DARE Long-Term Evaluations and Federal Efforts. 2003.
• ACLU. The War on Marijuana in Black and White. 2013 and 2020 update.
• Slater T. The killjoy state. Spiked, 14 September 2024.
• Spiked. Minimum unit pricing: it's pish. 2019.
• Public Health Scotland. Evaluating the Impact of MUP on Alcohol Consumption and Health. 2023 series.
• Society for Adolescent Health and Medicine. Position statement: abstinence-only-until-marriage education programs. 2017.
• UK Office for National Statistics. Deaths of people in contact with treatment services / post-release mortality. Annual series.
• CDC WONDER. US overdose mortality data. 2024 release.

Industry & political-economy sources

Shellenberger — San Fransicko and the addiction industrial complex

• Shellenberger M. San Fransicko: Why Progressives Ruin Cities. Harper, October 2021. The most-cited recent diagnostic of US West Coast harm-reduction failure modes. Steelmanned and taken apart on the Industry page; cross-referenced in the "90% of public policy fails" section on Structural.
• Public, Shellenberger's Substack — ongoing coverage of West Coast street outcomes and the harm-reduction-vs-accountability debate.

Narconon / Foundation for a Drug-Free World — the religious-cover case

• Foundation for a Drug-Free World — Wikipedia overview, including school-recruitment controversies.
• Narconon — Wikipedia case index covering deaths-in-care, pseudo-pharmacology, regulatory action.
• Boston Herald series (March 1998). The first major exposé of Scientology's school-access strategy.
• CBS News — Santa Monica High cancels Narconon programme after parents discover Scientology link.
• Hollywood Reporter investigation of Narconon's school programmes.
• McGill Office for Science and Society — analysis of the Truth About Drugs pamphlet's pseudo-pharmacology.

US 28-day rehab / Minnesota Model — evidence vs market dominance

• Recovery Research Institute — review of residential treatment outcomes. Documents the gap between market dominance and outcome evidence.
• Werb D et al. — Cochrane review of compulsory drug treatment, International Journal of Drug Policy, 2016. Found no consistent evidence of effectiveness for compelled treatment compared to voluntary OST.

Public-policy base rate — the 90% fails challenge

• Pressman JL & Wildavsky A. Implementation. University of California Press, 1973. The foundational text on the gap between policy intention and execution.
• Scott JC. Seeing Like a State. Yale University Press, 1998. Why state-legibility projects fail.
• Easterly W. The White Man's Burden. Penguin Press, 2006. The aid-policy failure pattern at international scale.
• Tetlock PE. Superforecasting. Crown, 2015. Expert-prediction calibration and what to do about it.
• Education Endowment Foundation (UK) — Teaching & Learning Toolkit and RCT pipeline. Source for the ~80% null-effect base rate cited in the Structural 90%-fails section.

Structural intervention sources

Iceland — Planet Youth

• Planet Youth — Icelandic Prevention Model overview.
• Sigfúsdóttir ID et al. Substance use prevention for adolescents: the Icelandic Model. Health Promotion International, 2009.
• Tarragona / IPM scoping review, 2023. International-replication results.
• UBC OSOT scoping review of international IPM adoption, 2025.

Medellín — social urbanism

• Globe and Mail — social urbanism under Fajardo.
• Americas Quarterly — Medellín: Front Line of Colombia's Challenges.
• International Crisis Group — Kids on the Front Lines: Stopping Child Recruitment in Colombia.
• IPA — Understanding How to Reduce Adolescent Recruitment into Gangs: Evidence from Medellín.

UK structural interventions — smoking, sugar, alcohol

• ASH 2024 — Economic Impact of Smoking.
• Public Health England — Health Matters: Smoking and Quitting in England.
• Chipty review for Australian Treasury — plain-packaging post-implementation analysis, 2016.
• Pell D et al. — Soft Drinks Industry Levy and changes in sugar content, BMJ, 2020. Industry-reformulation claim.
• Rogers NT et al. — SDIL and adolescent obesity, JAMA Pediatrics, 2024. Contested girls-only effect.
• Public Health Scotland — MUP final evaluation report, 2023.
• Wyper GMA et al. — MUP and alcohol-attributable deaths, Lancet, 2023. Synthetic-control counterfactual.

Countries page sources

France — primary-care buprenorphine

• Auriacombe M et al. — French buprenorphine experience, American Journal on Addictions, 2004.

Switzerland — heroin-assisted treatment

• EMCDDA Insights — Heroin-Assisted Treatment. Multi-country RCT review including the Swiss programme.

Portugal — decriminalisation

• Hughes CE & Stevens A. What can we learn from the Portuguese decriminalization of illicit drugs? British Journal of Criminology, 2010.

The expert voices — quoted within the panel and pathway

Chris Snowdon

• Velvet Glove, Iron Fist: A History of Anti-Smoking (2009)
• The Art of Suppression: Pleasure, Panic and Prohibition since 1800 (2011)
• Killjoys: A Critique of Paternalism (IEA, 2017)
• IEA Discussion Papers: Alcohol and the Public Purse (2015), Smoking and the Public Purse (2017), Defanging the Nanny State (2024) — all linked above

Carl Hart

• Hart CL. Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear. Penguin, 2021.
• Los Angeles Review of Books interview.
• NPR review, January 2021.
• Wyoming Public Media interview, 2022.

Maia Szalavitz

• Szalavitz M. Unbroken Brain: A Revolutionary New Way of Understanding Addiction. St Martin's Press, 2016.
• Szalavitz M. Undoing Drugs. Hachette, 2021.
• HealthCity summary.

Marc Lewis

• Lewis M. The Biology of Desire: Why Addiction Is Not a Disease. PublicAffairs, 2015.
• Lewis M. Memoirs of an Addicted Brain. PublicAffairs, 2011.
• Lewis M. Addiction and the Brain: Development, Not Disease. Neuroethics, 2017.
• UNSW NDARC interview.

Nora Volkow

• Volkow ND, Koob GF, McLellan AT. Neurobiologic Advances from the Brain Disease Model of Addiction. NEJM, 2016.
• Volkow ND & Koob GF. Brain disease model of addiction: why is it so controversial? Lancet Psychiatry, 2015.
• NIDA / NIAAA commentary on the brain-disease model.

The peer-reviewed in-house critique

• Hall W, Carter A & Forlini C. The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises? Lancet Psychiatry, 2015.

Editorial flags & honest gaps

What the site does not yet have, by category:

• UK-specific opioid cost-of-illness figure. The literature is dominated by US numbers. A UK equivalent of the Florence 2021 paper would strengthen the costs page.
• Direct head-to-head tirzepatide mortality data in obese non-diabetics. SURMOUNT-MMO reads out 2027–28. The current actuarial case extrapolates from SELECT and SURPASS-CVOT; the extrapolation is reasonable but not yet a substitute for the direct trial.
• Long-run safety data on GLP-1 / GIP agonists at 15–20 years. Longest RCT exposure is currently ~3 years. The unknown is material for cosmetic / off-label use.
• Verbatim Snowdon quotation from inside the Killjoys text. The IEA paper claims and press releases are cited; the inside-the-book quotations require a copy in hand to extract cleanly.
• Volkow opening sentence of the 2016 NEJM paper. Cited via paraphrase consistent with the published abstract. Verbatim opening line would require paywall access.
• Spiked's specific Mounjaro / Ozempic editorial line. Runs through the killjoy-state and drink-and-drugs streams; does not exist as a single titled article in the searched corpus.
• Pornography cost-of-illness. No credible figure exists. The site says so explicitly; this is a genuine literature gap, not a research failure on the site's part.

Any reader wanting to push back on a specific claim is invited to do so by reference to the primary source. The site is a defended thesis; the defence stops at the evidence, and the evidence is on this page.